Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 43 out of 100. Risk factors

Topic: Risk, prevention and care in population studies

Plain-language summary

The national prevalence and incidence of registered dementia diagnoses was 3.0% and 0.5%, respectively. The proportion of patients diagnosed at a dementia specialist department ranged from 60.9% to 90.5% across the five regions, subtype specific diagnosis ranged from 45.3% to 75.5%, and use of anti-dementia medication ranged from 29.2% to 58.3%. The observed geographical variations in dementia diagnoses and treatment indicate inequality in the access to appropriate diagnostic evaluation and care for patients with dementia. Our findings call for more awareness of the benefits of timely diagnosis and for improvement in the quality of diagnostic evaluation of dementia.

What this study adds

Evidence grade: Low

This is a cross-sectional study. This study found that dementia diagnosis rates and use of anti-dementia medication varied widely across five regions, indicating unequal access to diagnosis and care. Reported effect size: 3.0%; 0.5%; 60.9% to 90.5%.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Zakarias, J. K., Jensen‐Dahm, C., Nørgaard, A., Roos, P., Gasse, C., Phung, T. K. T., et al. (2019). Geographical Variation in the Diagnostic Rate and Quality of Dementia Diagnoses. Journal of Alzheimer s Disease. https://doi.org/10.3233/jad-190030

Vancouver

Zakarias JK, Jensen‐Dahm C, Nørgaard A, Roos P, Gasse C, Phung TKT, et al. Geographical Variation in the Diagnostic Rate and Quality of Dementia Diagnoses. Journal of Alzheimer s Disease. 2019. doi:10.3233/jad-190030. PMID: 30958374.

BibTeX

@article{zakarias2019-30958374,
  author  = {Zakarias, Johanne Købstrup and Jensen‐Dahm, Christina and Nørgaard, Ane and Roos, Peter and Gasse, Christiane and Phung, Thien Kieu Thi and Waldemar, Gunhild},
  title   = {{Geographical Variation in the Diagnostic Rate and Quality of Dementia Diagnoses}},
  journal = {Journal of Alzheimer s Disease},
  year    = {2019},
  doi     = {10.3233/jad-190030},
  pmid    = {30958374},
  url     = {https://doi.org/10.3233/jad-190030}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record names 7 authors; APA and Vancouver show the first six, BibTeX and the downloads carry all of them. Check the citation against the original before you use it.

Key findings

Why it matters

This study found that dementia diagnosis rates and use of anti-dementia medication varied widely across five regions, indicating unequal access to diagnosis and care. It does not test a treatment or prevention, so it cannot show how to cure or prevent dementia.

Study details

How this study scored 43/100
How this study's score is builtJournal tier 7 of 10; Journal's citation record 2 of 4; Study design 4 of 12; Strength of evidence 1 of 5; Peer-review validation 10 of 10; How recent 2 of 5; Sample size 0 of 4; Effect reported 2 of 3; Studied in people 0 of 3; Randomized / blinded 0 of 2; Times cited 3 of 7; Citations per year 1 of 5; Impact for its field and year 2 of 6; Cited by studies here 0 of 6; Still being cited 1 of 4; Senior author's track record 3 of 4; Institution's track record 1 of 3; Multicenter collaboration 2 of 3; Indexed in PubMed 2 of 2; Free to read 0 of 2. Total 43 of 100.43 of 100 points earned57 not earned

Published in a peer-reviewed journal, and it is a snapshot of people at one point in time. Scored zero for sample size, studied in people and randomized / blinded because the record does not state it.

ComponentPointsWhy
Journal tier 7 / 10 Tier 3 — peer-reviewed journal (Journal of Alzheimer s Disease)
Journal's citation record 2 / 4 Journal of Alzheimer s Disease: journal h-index 218 (OpenAlex, 2026-10-29)
Study design 4 / 12 A snapshot of people at one point in time
Strength of evidence 1 / 5 Rated “low” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 2 / 5 2019 — within 10 year(s) of the newest study here
Sample size 0 / 4 Participant count not stated — scores zero (not stated in the record — scored 0)
Effect reported 2 / 3 Effect reported as a number, without an interval or test
Studied in people 0 / 3 Not stated whether this was studied in people — scores zero (not stated in the record — scored 0)
Randomized / blinded 0 / 2 No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 3 / 7 Cited 20 times (OpenAlex, 2026-10-10)
Citations per year 1 / 5 2.2 citations a year over 9 year(s) since 2019
Impact for its field and year 2 / 6 Cited 1.8× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 0 / 6 No other study in this library cites it
Still being cited 1 / 4 Cited 7 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 3 / 4 Last-listed author Gunhild Waldemar: h-index 80 (OpenAlex, whole career)
Institution's track record 1 / 3 University of Copenhagen: institution h-index 1,378 (OpenAlex)
Multicenter collaboration 2 / 3 OpenAlex lists 4 institution(s) in 1 country
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 30958374)
Free to read 0 / 2 Behind a paywall — scores zero
Total 43 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

May need a subscription OpenAlex found no free copy of the full text (checked 6 Feb 1020), so the publisher may charge for it. The PubMed abstract is free.

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here.

Related studies in Risk factors from nearby years

Also tagged “prevalence”

1,225 studies in the library carry the topic tag “prevalence”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 1,225 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Risk factors

See all studies in Risk factors →